From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Hotdogs and motorways: The ripples created by Denmark's Ozempic and Wegovy boom
American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...
New weight loss drugs aim to promote muscle growth
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Why the market has missed a trick for this weight loss drug
Northcape Capital’s Wendy Herringer isn’t deterred by the 40 per cent crash in Novo Nordisk and is all in on a waste disposal ...
manilatimes6h
Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications
CardCash.com, Giftify's secondary gift card exchange platform, provides consumers with an innovative approach to reduce rising out-of-pocket expenses for increasingly popular GLP-1 medications. The ...
‘We made 434pc on one stock – now we’re hunting for the next Ozempic’
Polar Capital Global Healthcare, which is co-managed by James Douglas, currently trades at a 3pc discount to its assets.
Pharmaceutical Technology1h
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.
Lexaria Bioscience Corp.: Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...